Dr. Reddy's Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dr. Reddy's Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 37% in 3 years, but profit fell: ₹2 less profit per ₹100 of extra sales. Lower than 88% of Healthcare companies in India.
- Cash Locked Ratio: For every ₹100 of sales, ₹45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹37 tied up three years earlier. More money tied up than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹96Over the last 3 years, every ₹100 of reported profit came with ₹96 of operating cash.
Lower than 55% of Healthcare companies in India.
Self-Funding Ratio
1.5×Over the last 3 years its own operating cash covered its investment spending (capex) 1.5 times.
Higher than 57% of Healthcare companies in India.
Cash Locked Ratio
₹45For every ₹100 of sales, ₹45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹37 tied up three years earlier.
More money tied up than 85% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
−₹2Sales grew 37% in 3 years, but profit fell: ₹2 less profit per ₹100 of extra sales.
Lower than 88% of Healthcare companies in India.
Asset Productivity Ratio
+37% / +80%In 3 years sales changed by +37% while total assets changed by +80%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.9×Debt due within a year is covered 0.9 times by its yearly operating cash.
Lower than 56% of Healthcare companies in India.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 65% of Healthcare companies in India.
Tangible Assets Ratio
80%Of every ₹100 the company owns, ₹80 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 82% of Healthcare companies in India.
Tangible Net Worth Ratio
69%Of every ₹100 of net worth, ₹69 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 81% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Dr. Reddy's Laboratories Limited owes ₹0.33 for every ₹1 it owns. Net profit fell 24% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
31.2Investors pay ₹31.2 for every ₹1 of Dr. Reddy's Laboratories Limited's yearly profit, lower than 62% of Healthcare companies in India.
P/B ratio
2.69The share price is 2.69 times Dr. Reddy's Laboratories Limited's book value per share, lower than 75% of Healthcare companies in India.
Market cap
₹103,207 CrThe total market value of all of Dr. Reddy's Laboratories Limited's shares at today's price (share price × number of shares), larger than 95% of Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹38,343 CrWhat Dr. Reddy's Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
₹460.30Net worth divided by the number of shares. The share price of ₹1,239 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
8.8%Dr. Reddy's Laboratories Limited earned 8.8% on its shareholders' money over the last year, lower than 71% of Healthcare companies in India.
Owes vs Owns
0.33×Dr. Reddy's Laboratories Limited owes ₹0.33 for every ₹1 it owns (low), lower than 60% of Healthcare companies in India.
Dividend yield
0.67%Dr. Reddy's Laboratories Limited pays 0.67% of its share price as dividends a year, higher than 73% of dividend-paying Healthcare companies in India.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit growth
-24%Net profit fell 24% in the year to Mar 2026, and shrank 2% a year on average over 3 years.
Profit margin
12.8%Dr. Reddy's Laboratories Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Dr. Reddy's Laboratories Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
13.4×Dr. Reddy's Laboratories Limited's operating profit covered its interest costs 13.4 times in the year to Mar 2026.
Cash vs debt
Net cashDr. Reddy's Laboratories Limited held ₹1,047 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Dr. Reddy's Laboratories Limited's P/E ratio?
Investors pay ₹31.2 for every ₹1 of Dr. Reddy's Laboratories Limited's yearly profit, lower than 62% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dr. Reddy's Laboratories Limited: ₹103,207 Cr ÷ ₹38,343 Cr (30 Jun 2026) = 2.7.
What is Dr. Reddy's Laboratories Limited's return on equity?
Dr. Reddy's Laboratories Limited earned 8.8% on its shareholders' money over the last year, lower than 71% of Healthcare companies in India.
How much does Dr. Reddy's Laboratories Limited owe compared with what it owns?
Dr. Reddy's Laboratories Limited owes ₹0.33 for every ₹1 it owns (low), lower than 60% of Healthcare companies in India.
Does Dr. Reddy's Laboratories Limited pay a dividend?
Yes. Dr. Reddy's Laboratories Limited pays 0.67% of its share price as dividends a year, higher than 73% of dividend-paying Healthcare companies in India.
Is Dr. Reddy's Laboratories Limited's revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.